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Abstract
SU5416 was originally designed as a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-
2) for cancer therapy. In this study, we have found for the first time that SU5416 unexpectedly prevented 1-methyl-4-
phenylpyridinium ion (MPP+)-induced neuronal apoptosis in cerebellar granule neurons, and decreased 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced loss of dopaminergic neurons and impairment of swimming behavior in
zebrafish in a concentration-dependent manner. However, VEGFR-2 kinase inhibitor II, another specific VEGFR-2 inhibitor,
failed to reverse neurotoxicity at the concentration exhibiting anti-angiogenic activity, strongly suggesting that the
neuroprotective effect of SU5416 is independent from its anti-angiogenic action. SU5416 potently reversed MPP+-increased
intracellular nitric oxide level with an efficacy similar to 7-nitroindazole, a specific neuronal nitric oxide synthase (nNOS)
inhibitor. Western blotting analysis showed that SU5416 reduced the elevation of nNOS protein expression induced by
MPP+. Furthermore, SU5416 directly inhibited the enzyme activity of rat cerebellum nNOS with an IC50 value of 22.7 mM. In
addition, knock-down of nNOS expression using short hairpin RNA (shRNA) abolished the neuroprotective effects of SU5416
against MPP+-induced neuronal loss. Our results strongly demonstrate that SU5416 might exert its unexpected
neuroprotective effects by concurrently reducing nNOS protein expression and directly inhibiting nNOS enzyme activity.
In view of the capability of SU5416 to cross the blood-brain barrier and the safety for human use, our findings further
indicate that SU5416 might be a novel drug candidate for neurodegenerative disorders, particularly those associated with
NO-mediated neurotoxicity.
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Introduction
SU5416 (Semaxanib) was originally designed as a potent and
selective inhibitor of vascular endothelial growth factor receptor-2
(VEGFR-2) for cancer therapy [1]. It occupies the ATP binding
site of VEGFR-2, and thereby abolishes vascular endothelial
growth factor (VEGF) signaling [1]. In the pre-clinical studies,
SU5416 inhibits VEGF-dependent angiogenesis both in vitro and in
vivo [2]. As the first VEGFR-2 inhibitor evaluated in clinical trial,
SU5416 is well tolerated even at the concentration of 145 mg/m2
in patients with advanced malignancies in phase I clinical study
[3]. It was found that SU5416 and 5-fluorouracil-leucovorin in
combination showed better efficacy than standard 5-fluorouracil-
leucovorin therapy in the pilot phase I/II study [4]. Nevertheless,
test on this drug was discontinued for there were no significant
clinical benefits in a randomized phase III trial [5]. Notably,
SU5416 could be rapidly distributed to all organs, and accumu-
lated in orthotopically implanted central nerve system (CNS)
tumor model and in patients with refractory pediatric CNS
tumors, suggesting that SU5416 could be delivered to the CNS by
passing through the blood-brain barrier [6].
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder among the elderly worldwide
[7,8,9]. Although the etiology of PD remains largely unknown,
overproduction of nitric oxide (NO) is considered as a causative
factor for the loss of dopaminergic neurons [10]. High levels of
neuronal nitric oxide synthase (nNOS) are found in the
nigrostriatal regions and basal ganglia of post-mortem PD
brains and animals treated with 1-methyl-4-phenyl-1,2,3,6-
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tetrahydropyridine (MPTP), a PD-inducing neurotoxin [11]. On
the other hand, transgenic mice that lack the nNOS gene are
more resistant to MPTP than wild-type mice [12]. Selective
nNOS inhibitors produce neuroprotective effects against MPTP
both in vitro and in vivo. These results suggest that nNOS
inhibitors might have therapeutic potential in the treatment of
PD [10,13,14,15].
Zebrafish serves as a good animal model to screen neuropro-
tective drugs [16,17]. MPTP could induce the loss of dopaminer-
gic neurons, decrease tyrosine hydroxylase expression in the
posterior tuberculum of the ventral diencephalon, and subse-
quently impair motor behavior in zebrafish [17]. In this study, we
first evaluated the neuroprotective activity of SU5416 against 1-
methyl-4-phenylpyridinium ion (MPP+), the active metabolite of
MPTP, induced neuronal death in primary cerebellar granule
neurons (CGNs) and MPTP-induced dopaminergic neuronal loss
and locomotion behavior impairment in zebrafish. We further
demonstrated that SU5416 might exhibit neuroprotective effects
by reducing nNOS expression and directly inhibiting nNOS
activity rather than by suppressing angiogenesis as previously
reported. The neuroprotective effect of SU5416 was also
confirmed by experiments using short hairpin RNA (shRNA)
knock-down of the NOS proteins in PC12 cells.
Materials and Methods
Ethics Statement of Animal Experiments
All rodent experiments were conducted according to the ethical
guidelines of Animal Subjects Ethics Sub-committee (ASESC), the
Hong Kong Polytechnic University; and the protocol was
approved by ASESC, the Hong Kong Polytechnic University
(permit number: 10/15). All surgeries were performed under
sodium pentobarbital anesthesia, and all efforts were made to
minimize animal suffering.
All zebrafish experiments were conducted according to the
ethical guidelines of Institute of Chinese Medical Sciences (ICMS),
University of Macau; and the protocol was approved by ICMS,
University of Macau.
Primary Cerebellar Granule Neuron Cultures
Rat CGNs were prepared from 8-day-old Sprague-Dawley rats
(The Animal Care Facility, The Hong Kong Polytechnic
University) as described in our previous publication [18]. Briefly,
neurons were seeded at a density of 2.76105 cells/ml in basal
modified Eagle’s medium (Invitrogen) containing 10% fetal bovine
serum, 25 mM KCl, 2 mM glutamine, and penicillin (100 units/
ml)/streptomycin (100 mg/ml). Cytosine arabinoside (10 mM) was
added to the culture medium 24 hours after plating to limit the
growth of non-neuronal cells. With the use of this protocol, more
than 95% of the cultured cells were granule neurons.
Measurement of Neurotoxicity
The percentage of surviving neurons in the presence of SU5416
and/or MPP+ was estimated by determining the activity of
mitochondrial dehydrogenases with 3(4,5-dimethylthiazol-2-yl)-
2.5-diphenyltetrazolium bromide (MTT) assay [13]. The assay
was performed according to the specifications of the manufacturer
(MTT kit I; Roche Applied Science). Briefly, the neurons were
cultured in 96-well plates, 10 ml of 5 mg/ml MTT labeling
reagent was added to each well containing cells in 100 ml of
medium, and the plates were incubated at 37uC for 4 hours in a
humidified incubator. After the incubation, 100 ml of the solvating
solution (0.01 N HCl in 10% SDS solution) was added to each well
for 16–20 hours. The absorbance of the samples was measured at
Figure 1. SU5416 prevents MPP+-induced apoptosis in a
concentration-dependent manner. (A) SU5416, but not VRI,
prevented MPP+-induced cell death in a concentration-dependent
manner. CGNs were treated with SU5416, VRI, EPTU, 7-nitroindazole (7-
NI), 1400 W or DMSO (vehicle control) at the indicated concentrations
for 2 hours and then exposed to 35 mM MPP+. Cell viability was
measured by MTT assay at 24 hours after MPP+ challenge. (B) SU5416
blocked neuronal loss induced by MPP+. CGNs were pre-incubated with
or without 20 mM SU5416 and exposed to 35 mM MPP+2 hours later. At
24 hour after MPP+ challenge, CGNs were assayed with FDA/PI double
staining. (C) SU5416 reversed the morphological alteration induced by
MPP+. CGNs were pre-incubated with or without 20 mM SU5416 and
exposed to 35 mM MPP+2 hours later. At 24 hour after MPP+ challenge,
CGNs were assayed with nNOS and Hoechst double staining. (D) The
number of apoptotic nuclei with condensed chromatin was counted
from representative Hoechst staining photomicrographs and repre-
sented as a percentage of the total number of nuclei counted. Data,
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a wavelength of 570 nm with 655 nm as a reference wavelength.
Unless otherwise indicated, the extent of MTT conversion in cells
exposed to MPP+ is expressed as a percentage of the control.
Cytotoxicity was determined by measuring the release of lactate
dehydrogenase (LDH). Briefly, cells were precipitated by centri-
fugation at 500 g for 5 min at room temperature, 50 ml of the
supernatants was transferred into new wells, and LDH was
determined using the in vitro toxicology assay kit (Roche). The
absorbance of the samples was measured at a wavelength of
490 nm with 655 nm as a reference wavelength.
FDA/PI Double Staining Assay
Viable granule neurons were stained with fluorescein formed
from fluorescein diacetate (FDA) by esterase in viable cells.
Propidium iodide (PI) can penetrate cell membranes of dead cells
to intercalate into double-stranded nucleic acids. Briefly, after
incubation with 10 mg/ml of FDA and 5 mg/ml of PI for 15 min,
the neurons were examined and images were acquired using UV
light microscopy for comparison with photos taken under phase
contrast microscopy.
Hoechst Staining and Immunostaining
Chromatin condensation was detected by staining the cell
nucleus with Hoechst 33342 as described in our previous
publication [18]. CGNs (2.76106 cells) grown in a 35-mm dish
were washed with ice-cold phosphate-buffered saline (PBS), fixed
with 4% formaldehyde in PBS, membrane-permeabilized in 0.1%
Triton X-100 and blocked in 1% BSA. Cells were then exposed to
a primary nNOS antibody (Santa Cruz) overnight at 4uC followed
by incubation at room temperature with an Alexa Fluor 488-
conjugated secondary antibody. After immunostaining, cells were
then stained with Hoechst 33342 (5 mg/ml) at 4uC for 5 min.
Images were acquired using a fluorescence microscope at 6100
magnification.
To quantify the percentage of apoptotic nuclei in each group,
photos of each dish (n = 3 dishes in each group for three
independent experiments) were taken at five random fields and
the numbers of apoptotic nuclei and total nuclei (n = 300) were
counted, and the percentage of apoptotic nuclei was averaged.
Measurement of Intracellular NO
Intracellular NO was monitored with (4-amino-5-methylamino-
29,79-difluorofluorescein) DAF-FM diacetate, a pH-insensitive
fluorescent dye that emits increased fluorescence after reaction
with an active intermediate of NO formed during the spontaneous
oxidation of NO to NO2 [19]. DAF-FM solution was added to the
culture medium (final concentration: 5 mM). After incubation for
30 min in a CO2 incubator, cultures were washed twice with PBS
and incubated for another 30 min to allow complete de-
esterification of the intracellular diacetate for strong fluorescence.
The DAF-FM fluorescence in CGNs was quantified by a multi-
detection microplate reader using excitation and emission
wavelengths of 495 nm and 515 nm, respectively. The measured
fluorescence values were expressed as a percentage of the
fluorescence in the control cells.
Western Blotting Analysis
Briefly, neurons were harvested in a cell lysis buffer. Protein was
separated on SDS–polyacrylamide gel and transferred onto
polyvinyldifluoride membranes. After membrane blocking, pro-
teins were detected using primary antibodies. After incubation at
4uC overnight, signals were obtained after binding to chemilumi-
nescent secondary antibodies. Blots were developed using an ECL
plus kit (Amersham Bioscience, Aylesbury, UK) and exposed to
Kodak autoradiographic films. All data were from three indepen-
dent experiments and were expressed as the ratio to optical density
(OD) values of the corresponding controls for statistical analyses.
Maintenance of Zebrafish and Drug Treatment
Wild-type zebrafish (AB strain) and Tg(fli-1:EGFP) transgenic
zebrafish were maintained as described in the Zebrafish Hand-
book [20]. Zebrafish embryos were generated by natural pair-wise
mating (3–12 months old) and were raised at 28.5uC in embryo
medium (13.7 mM NaCl, 540 mM KCl, pH 7.4, 25 mM
Na2HPO4, 44 mM KH2PO, 300 mM CaCl2, 100 mM MgSO4,
420 mM NaHCO3, pH 7.4). Drugs were dissolved in DMSO and
directly added into zebrafish embryo medium to treat fish without
refreshing in 2–3 days (Final concentration of DMSO was always
less than 0.5%, and showed no toxicity to zebrafish). Equal
concentration of DMSO in embryo medium was used as vehicle
control in each experiment.
Exposure of Zebrafish to MPTP
Healthy zebrafish embryos were picked and dechorionated
manually at 1 day post fertilization (dpf) then distributed into a 12-
well plate with 20 fish embryos or a 6-well microplate with 30 fish
embryos in each well. In pilot experiments, several doses of MPTP
were added to embryo medium (final concentration from 50 to
800 mM) and 1 dpf fish embryo were treated for 48 hours, The
optimal dose used (200 mM) induced a significant decrease in brain
diencephalic dopaminergic neurons without any detectable
systematic toxicity (data not shown). Thus subsequent studies
were performed with 200 mM MPTP for whole-mount immuno-
staining and gene expression experiments.
Normally as late as 3 dpf, zebrafish larvae show very little
spontaneous swimming, but by 5 dpf they spontaneously swim
longer distances and independently search for food. The MPTP
exposure therefore needs to last 5 days from 1 dpf. In pilot
locomotion behavioral test, 3-day treatment starting from 1 dpf
with 200 mM MPTP in embryo medium killed all the fish larvae,
however, after 2-day treatment at 1 dpf with 200 mM MPTP then
withdraw 3 days, and the deficit behavior recovered at 6 dpf.
Finally, the optimal MPTP exposure was after 2-day treatment
starting from 1 dpf with 200 mM MPTP, zebrafish larvae were
maintained in embryo medium containing 10 mM MPTP for
another 3 days, the swimming distance significantly decreased and
without any detectable systematic toxicities. Thus subsequent
locomotion behavioral studies were performed with 200 mM
MPTP for 2-day treatment at 1 dpf then replacing with media
containing 10 mM MPTP for another 3-day incubation.
Whole-mount Zebrafish Immunostaining with Antibody
against Tyrosine Hydroxylase
Whole-mount immunostaining in zebrafish was performed as
before [21]. Briefly, zebrafish were fixed in 4% paraformaldehyde
(wt/vol in PBS) for 5 h at room temperature or overnight at 4uC,
washed with PBS 3 times, then kept in absolute ethanol at 220uC
to dehydrate for at least 2 h or up to 1 week. Fixed samples were
bleached in 10% H2O2 then blocked (2% lamb serum and 0.1%
expressed as percentage of control, were the mean 6 SEM of three
separate experiments; *p,0.05 and **p,0.01 versus MPP+ group in (A)
or versus control in (D); ##p,0.01 versus MPP+ group in (D) (Turkey’s
test).
doi:10.1371/journal.pone.0046253.g001
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BSA in PBST) for 1 h at room temperature. A mouse anti-tyrosine
hydroxylase (TH) monoclonal antibody (Millipore, USA) was used
as the primary antibody and incubated with the sample overnight
at 4uC. On the next day, samples were washed 6 times with PBST
(30 min each wash), followed by incubation with secondary
antibody according to the method provided by the Vectastain
ABC kit (Vector Laboratories, USA). After staining, zebrafish were
flat-mounted with 3.5% methylcellulose and photographed. Semi-
quantification of area of TH+ region was assessed by an
investigator blinded to the drug treatment history of zebrafish
using Image-Pro Plus 6.0 software (Media Cybernetics, Silver
Spring, MD, USA). Results were expressed as percentage of area
of TH+ region in untreated control group.
Paraffin-embedding, Serial Sectioning and
Immunostaining of Zebrafish Larval
After drug treatment, fixation of zebrafish larval was performed
as the procedure in whole-mount immunostaining. We then
mounted fixed specimens on 1% agarose blocks in a common
linear plane to ensure that the microtome blade passes through
each specimen simultaneously. The specimen-containing agarose
Figure 2. SU5416 protects against MPTP-induced TH+ region area decrease in zebrafish. One dpf zebrafish embryos were co-incubated
with 200 mM MPTP and SU5416, VRI or 0.3% DMSO (vehicle control) at the indicated concentrations for 2 days. After treatment, zebrafish were
collected to perform whole-mount immunohistochemistry. (A) Representative pictures of whole-mount immunostaining of zebrafish brain from
different treatment groups. (B) Magnification of diencephalic area of zebrafish larval (indicated by red bracket in Fig. 2A). (C) Statistical analysis of TH+
region area in each treatment group (20 fish embryos per group). Data, expressed as percentage of control, were the mean 6 SEM of three separate
experiments; ##p,0.01 versus control; *p,0.05 and **p,0.01 versus MPTP group (Turkey’s test).
doi:10.1371/journal.pone.0046253.g002
Neuroprotection of SU5416 against MPP+
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was converted into a sectionable paraffin wax block and conducted
processes as described by Sabaliauskas et al. [22]. Consecutive
coronal sections were cut 5 mM thick using a rotary microtome
(Leica RM2235, Germany) and mounted on microscope slides.
Immunostaining of zebrafish larval sections was performed as
previously described [23] with minor modifications. Paraffin
sections were deparaffinized in xylene, hydrated in graduated
alcohol solutions and incubated for 30 min in 3% H2O2 in PBS to
inactivate endogenous peroxidases. Following antigen retrieval in
citrate buffer for 15 min in a microwave oven, sections were
blocked at room temperature with 10% horse serum for 1 hour.
Sections were reacted overnight at 4uC with rabbit anti-mouse TH
polyclonal antibody (Millipore, USA) at 1:400 dilutions in
immunostaining primary antibody dilution buffer (Beyotime,
China). For detection of primary antibody, the EnVision
Detection kit (Gene Tech., Shanghai, China) was used. Detection
was done by the appropriate second antibody with peroxidase
conjugate and DAB substrate. Finally, sections were coverslipped
with neutral balsam. The results were analyzed by counting the
numbers of TH-positive cells at 620 magnifications on a
stereomicroscope (BX51, Olympus Corp. Japan). TH-positive
cells in 3 matched sections of each zebrafish were counted and
averaged. 12 fish per treatment group were employed. The
average number of TH-positive cells per section was used to
represent dopaminergic neuron livability.
Figure 3. SU5416 increases the number of dopaminergic neurons in MPTP-treated zebrafish larval. One dpf zebrafish embryos were co-
incubated with 200 mM MPTP and 1 mM SU5416 or 0.3% DMSO (vehicle control) for 2 days. After treatment, zebrafish were collected to perform
paraffin-embedding, sectioning and immunostaining. (A) Representative picture of immunostaining of zebrafish section. (B) Statistical analysis of the
number of TH-positive neurons in each treatment group (n = 12 fish/group). *p,0.05 versus MPTP group (Turkey’s test).
doi:10.1371/journal.pone.0046253.g003
Figure 4. SU5416 attenuates the deficit of locomotion behavior on zebrafish larval induced by MPTP. One dpf zebrafish embryos were
treated with 200 mM MPTP for 2 days, and then co-incubated with 10 mM MPTP and SU5416 or VRI at the indicated concentrations for 72 hours, and
zebrafish larval co-treated with MPTP and 150 mM L-dopa or 20 mM L-deprenyl were used as positive controls. After treatment, zebrafish were
collected to perform locomotion behavior test using Viewpoint Zebrabox system and total distances travelled in 10 min were calculated. Data,
expressed as percentage of control, were the mean 6 SEM of 12 fish larvae per group from 3-time independent experiments. ##p,0.01 versus
control group; **p,0.01 versus MPTP group (Turkey’s test).
doi:10.1371/journal.pone.0046253.g004
Neuroprotection of SU5416 against MPP+
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Locomotion Behavioral Test of Zebrafish
After drug treatment, zebrafish larvae at 6 dpf were transferred
into 96-well plates (1 fish/well and 12 larvae/group). The larvae
were discarded due to excessive stress reaction to the handling and
monitoring of behavior (such as rapid and disorganized swimming
or immobility for 2 min). The experiments were performed in a
calm sealed area. The larvae were allowed to habituate to the new
environment for 30 min. Swimming behavior was monitored by
an automated video tracking system (Viewpoint, ZebraLab,
LifeSciences). The 96-well plates and camera were housed inside
a Zebrabox and the swimming pattern of each fish was recorded
for 10 min and for 3 times, once every other 10 min. The total
distance moved was defined as the distance (in cm) that the fish
had moved during one session (10 min).
Morphological Observation of Zebrafish
After drug treatment, zebrafish were removed from the
microplate and observed for gross morphological changes of
blood vessel under a fluorescence microscope (Olympus IX81
Motorized Inverted Microscope, Japan) equipped with a digital
camera (DP controller, Soft Imaging System, Olympus). Images
were analyzed with Axiovision 4.2 and Adobe Photoshop 7.0.
In vitro nNOS Activity Assay
Rat cerebellum nNOS was from Calbiochem. NOS activity was
determined by monitoring the conversion of L-[3H]arginine to
[3H]citrulline following the instructions provided by the kit
(Calbiochem). The reaction mixture contained a final volume of
40 ml with 25 mM Tris-Cl at pH 7.4, 3 mM tetrahydrobiopterin,
1 mM FAD, 1 mM FMN, 1 mMNADPH, 0.6 mM CaCl2, 0.1 mM
calmodulin, 2.5 mg of pure NOS enzyme, 5 ml L-[3H]arginine
(Perkin Elmer, Waltham, MA, USA), and different concentrations
of the tested reagents. The reaction mixture was incubated at 22uC
for 45 min. The reaction was quenched by adding 400 ml of
stopping buffer (50 mM HEPES, pH 5.5, and 5 mM EDTA).
Unreacted L-[3H]arginine was then trapped by 100 ml of
equilibrated resin in a spin cup followed by centrifugation at
13,200 rpm for 30 s.
Figure 5. Anti-angiogenic effects of SU5416 and VRI in
zebrafish. One dpf Tg(fli-1:EGFP) transgenic zebrafish embryos were
treated with SU5416, VRI or DMSO (vehicle control) at the indicated
concentrations for 2 days. After treatment, intersegmental-vessel
formations were observed under fluorescence microscopy. Deficit of
blood vessels was indicated by yellow asterisks.
doi:10.1371/journal.pone.0046253.g005
Figure 6. SU5416 reverses the elevated intracellular NO induced by MPP+ in CGNs. CGNs were pre-incubated with EPTU, 7-NI or SU5416 at
the indicated concentrations for 2 hours, and exposed to 35 mM MPP+. Intracellular NO level was measured using DAF-FM diacetate as a probe at 8
hour after MPP+ challenge. Data, expressed as percentage of control, were the mean 6 SEM of three separate experiments; **p,0.01 versus MPP+
group (ANOVA and Dunnett’s test).
doi:10.1371/journal.pone.0046253.g006
Neuroprotection of SU5416 against MPP+
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shRNA Design
ShRNA against rat nNOS was designed according to a previous
publication [24]. Briefly, the SiRNA sequence GCACUGGUG-
GAGAUCAACA, which corresponds to exon 10 of the rat nNOS
(GenBank Accession No. NM_052799), was used to generate
shRNA. Oligonucleotides that contained the sense and antisense
sequences of the siRNA target of interest flanking a standard
hairpin loop sequence (TTCAAGAGA) were synthesized. Sense
and antisense oligonucleotides were then annealed and cloned into
pG418-GFP vector to express shRNA directed against nNOS
under the control of the U6 promoter (GenePharma, Shanghai,
China). A negative control shRNA (ShNC) with the same
nucleotide composition but lacks significant sequence homology
to the genome was also used in the experiments.
Cell Transfection
PC12 pheochromocytoma cells were cultured in medium that
consisted of DMEM, 10% heat-inactivated horse serum, 5% fetal
bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin
in a 37uC, 5% CO2 incubator. 2.0610
5 cells were transfected with
3 mg indicated plasmids by using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Selection media that
Figure 7. SU5416 reduces the expression of nNOS protein elevated by MPP+ in CGNs. (A) CGNs were pre-treated with 20 mM SU5416 or
DMSO (vehicle control) for 2 hours, and then treated with 35 mM MPP+ for various durations as indicated. The total proteins were extracted for
Western blot analysis with specific iNOS, nNOS and b-actin antibodies. (B) Statistical analysis of nNOS expression in each treatment group. Data are
expressed as the ratio to OD values of the corresponding controls. Data, expressed as percentage of control, were the mean 6 SEM of five separate
experiments; *p,0.05 versus MPP+ group at the same time (Turkey’s test).
doi:10.1371/journal.pone.0046253.g007
Neuroprotection of SU5416 against MPP+
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contained 100 mg/ml G418 (Sigma) were added to the cells 24
hours after transfection.
Data Analysis and Statistics
Data are expressed as the means 6 SEM, and statistical
significance was determined by analysis of variance with Dunnett’s
test in the case of multiple comparisons with control or Turkey’s
test. Differences were accepted as significant at p,0.05.
Results
SU5416 Prevented MPP+-induced Neuronal Apoptosis in
a Concentration-dependent Manner
After cultured for 8 days in vitro, CGNs were pre-treated with
SU5416 at the concentrations of 3, 10, 20 or 30 mM for 2 hours,
and then treated with 35 mM MPP+ for another 24 hours. Cell
viability was measured using the MTT assay. It was found that
SU5416 prevented 35 mM MPP+-induced cell death in a
concentration-dependent manner (Fig. 1A). However, treatments
with 30 mM SU5416 alone for 26 hours did not produce any cell
proliferative or cytotoxic effects. VEGFR-2 kinase inhibitor II
(VRI), another specific VEGFR-2 inhibitor with an IC50 value of
70 nM, was also tested in this model. Interestingly, VRI at 1 and
3 mM failed to block neuronal loss in vitro (Fig. 1A).
To further characterize the effects of SU5416 on the
neurotoxicity of MPP+, CGNs were pretreated with 20 mM
SU5416 and exposed to 35 mM MPP+ for 2 hours. The neurons
were examined by FDA/PI double staining. It was found that
SU5416 significantly blocked the loss of neurons and reversed the
morphological alteration, including unhealthy bodies and broken
extensive neuritic network, induced by MPP+ (Figs. 1B and 1C).
According to the counts of apoptotic bodies stained by Hoechst
33342, SU5416 significantly reversed neuronal apoptosis induced
by MPP+ (Figs. 1C and 1D).
NO is implicated in the neurotoxicity of MPP+ [12,25]. To
investigate whether NO was involved in our neuronal apoptosis
model, nNOS immunostaining and NOS inhibitors were used to
treat neurons for 2 hours prior to the addition of MPP+. It was
observed that there were nNOS-positive neurons in our CGNs
(Fig. 1C). Moreover, a pan-NOS inhibitor 2-ethyl-2-thiopseu-
dourea (EPTU, IC50 values of 0.017 mM for iNOS. and 0.036 mM
for nNOS) prevented MPP+-induced neuronal death in CGNs
(Fig. 1A). The roles of NOS iso-enzymes were also examined by
using specific inhibitors. We found that the specific nNOS
inhibitor 7-nitroindazole (IC50 values of 0.7 mM for nNOS, and
20 mM for iNOS) protected against neuronal apoptosis in our
model, whereas iNOS inhibitor 1400 W (IC50 values of 0.007 mM
for nNOS, and 2 mM for iNOS) did not show protection (Fig. 1A).
SU5416 Prevented MPTP-induced Neurotoxicity in
Zebrafish
To assess the neuroprotective potential of SU5416 in vivo,
zebrafish embryos at 1 dpf were exposed to 200 mM MPTP for 2
days, and the dopaminergic system in the brain of zebrafish was
then examined by whole-mount immunostaining with specific
antibody against TH. After MPTP treatment, the area of TH-
immunoreactive regions observed in the diencephalons of
zebrafish (indicated by red brackets) were decreased dramatically
(Figs. 2A and 2B). Importantly, SU5416 (0.1–1 mM) significantly
prevented the decrease in the area of TH+ region induced by
MPTP. In contrast, VRI (0.03–0.3 mM) could not prevent MPTP-
induced decrease in TH+ region area in zebrafish (Fig. 2). Both
drugs at higher concentration, SU5416 at 10 mM and VRI at
3 mM, showed toxicity to zebrafish (data not shown).
To further confirm the protective effect of SU5416 against
MPTP-induced dopaminergic neurotoxicity and to accurately
observe changes of dopaminergic neurons in zebrafish, paraffin-
embedding, serial sectioning and immunostaining of zebrafish
larval were performed. TH-positive neuron count showed MPTP
Figure 8. SU5416 directly inhibits nNOS enzyme activity in a concentration-dependent manner. The inhibitory effects of SU5416 on rat
cerebellum nNOS were shown in the graph. The IC50 value was also indicated. Each individual point was an average from three independent
experiments.
doi:10.1371/journal.pone.0046253.g008
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treatment significantly decreased the number of dopaminergic
neurons, and 1 mM SU5416 co-treatment obviously prevented the
loss of dopaminergic neurons (Fig. 3). SU5416 treatment alone did
not notably alter the number of dopaminergic neurons.
As shown in Fig. 4, the total distance travelled by the zebrafish
larvae decreased significantly after exposure to MPTP. SU5416
but not VRI ameliorated the MPTP-induced deficit of swimming
behavior, which was also rescued by treatment with L-dopa and L-
deprenyl (selegiline) as positive controls. Neither SU5416 nor VRI
treatment alone notably altered the swimming behavior of normal
zebrafish larvae (Fig. 4).
The Neuroprotective Effects of SU5416 were not Directly
Correlated with its Anti-angiogenic Action
We further determined if SU5416 at particular concentration
ranges exhibited any anti-angiogenic activities in Tg(fli1:EGFP)
transgenic zebrafish embryos. Owing to the genetic addition of a
GFP gene under the control of the fli-1 promoter, the fli-1
promoter activity in the endothelial cells of such zebrafish model
can be directly observed using fluorescence microscopy. As shown
in Fig. 5, VRI (0.1–0.3 mM) inhibited the formation of interseg-
mental-vessels in zebrafish larvae, whereas SU5416 (0.3–1 mM)
did not show this activity.
SU5416 Prevented MPP+-induced Increase of Intracellular
NO Release
To investigate whether SU5416 protected against MPP+-
induced neurotoxicity from acting on NO release, an intracellular
NO measurement was used in our study. When CGNs were
treated with SU5416 and MPP+ simultaneously, SU5416 antag-
onized the stimulatory effect of MPP+ on the NO production with
an efficacy similar to 7-nitroindazole (15 mM) (Fig. 6). Our results
suggest that the neuroprotection of SU5416 against MPP+-
induced neuronal loss might be mediated by decreasing NO
neurotoxicity, probably by inhibiting nNOS over-activation.
SU5416 Reduced MPP+-increased Expression of nNOS
Protein
To determine the effect of SU5416 on the protein expressions of
nNOS and iNOS in CGNs, Western blotting analysis was used. As
shown in Fig. 7, SU5416 at 20 mM reversed the increased
expression of nNOS by MPP+. However, SU5416 at the same
concentration could not affect the elevated expression of iNOS by
MPP+ (Fig. 7A).
SU5416 Directly Inhibited the Activity of nNOS
Furthermore, to investigate whether SU5416 also affected the
activity of nNOS, an in vitro NOS activity assay was used in this
study. It was found that SU5416 directly inhibited rat cerebellum
nNOS in a concentration-dependent manner with an IC50 value
of 22.7 mM (Fig. 8). These results suggest that SU5416 not only
decreased the expression of nNOS, but also directly inhibited the
activity of nNOS.
nNOS Depletion Abolished the Neuroprotective Effects
of SU5416
To explore if the neuroprotective effects of SU5416 mainly act
through nNOS, we investigated the neuroprotection of SU5416
against MPP+-induced neurotoxicity in ShRNA-mediated nNOS
knockdown PC12 cells. Western blot analysis showed that nNOS
ShRNA (ShnNOS) caused a reduction in nNOS protein level,
whereas the negative control ShRNA (ShNC) had no effect on
nNOS protein level (Fig. 9A). Analyses of cell viability and
Figure 9. nNOS depletion abolishes the neuroprotective effects
of SU5416 against MPP+-induced neuronal death in PC12 cells.
(A) PC12 cells were transfected with pG418-GFP plasmid (vector),
pG418-GFP plasmid encoding nNOS ShRNA (ShnNOS) and pG418-GFP
plasmid encoding negative control ShRNA (ShNC). The levels of nNOS
and b-actin in the cell lysates were analyzed by Western blotting assay
by using specific antibodies. (B, C) nNOS depletion abolished the
neuroprotective effects of SU5416 against MPP+-induced neuronal
death in PC12 cells. PC12 cells transfected with vector, ShnNOS, or ShNC
were treated with 20 mM SU5416 for 2 hours and then exposed to
1 mM MPP+. Cell viability (B) and cytotoxicity (C) were measured at 24
hours after MPP+ challenge by MTT and LDH assays, respectively. Data
were the mean 6 SEM of three separate experiments; **p,0.01 versus
control; ##p,0.01 versus MPP+ group; &p,0.05 and &&p,0.01 versus
MPP+ vector group (Turkey’s test).
doi:10.1371/journal.pone.0046253.g009
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cytotoxicity revealed that nNOS depletion resulted in a significant
decrease in MPP+-induced cell death (Figs. 9B and 9C). We found
that, in contrast to the neuroprotection effects of SU5416 observed
in the vector or in the ShNC treated PC12 cells, SU5416 in nNOS
knockdown PC12 cells was no longer able to inhibit MPP+-
induced cell death (Figs. 9B and 9C). These results provided direct
supporting evidence that the neuroprotective effects of SU5416
mainly act through the nNOS enzyme.
Discussion
SU5416 is the first clinically evaluated VEGFR-2 inhibitor.
Although previous clinical trails did not recommend SU5416 as an
anti-cancer drug, SU5416 appeared to be safe in human use. In
this study, we demonstrated for the first time that SU5416 was a
promising neuroprotectant against MPP+/MPTP-induced neuro-
toxicity both in vitro and in zebrafish. Our results further revealed
that the neuroprotection of SU5416 was not closely correlated
with its anti-angiogenic action, but via attenuating NO-mediated
neurotoxicity, possibly by both decreasing nNOS protein expres-
sion and directly inhibiting nNOS enzyme activity.
SU5416 was originally designed as a potent VEGFR-2 inhibitor
with an IC50 value of 0.39 mM against the cellular VEGFR-2
tyrosine kinase activity [1]. To clarify whether its neuroprotection
was due to the inhibition of VEGFR-2-dependent angiogenesis,
another potent and selective VEGFR-2 inhibitor VRI was assessed
in parallel. Interestingly, SU5416 at its neuroprotective concen-
tration did not inhibit angiogenesis, whereas VRI did not prevent
neuronal loss at the concentration in which it showed potent anti-
angiogenic activity. These results suggest that the neuroprotection
of SU5416 was not closely correlated with its anti-angiogenic
property. Previous studies also showed that the activation of
VEGFR-2 promoted neuronal survival by regulating phosphoino-
sitide 3-kinase (PI3-K)/Akt and extracellular signal-regulated
kinase (ERK) pathways [26]. The PI3-K/Akt signaling pathway
is a pro-survival pathway, whereas the ERK pathway is a pro-
apoptotic pathway in MPP+-induced neuronal apoptosis in CGNs
[27]. To examine whether SU5416 acts on down-stream pathways
of VEGFR-2, such as the ERK and Akt pathways, to protect
against MPP+-induced neurotoxicity, we tested the activities of
phospho-Akt (pAkt) and phospho-ERK (pERK) in Western blot
assay (data not shown). Our results show that SU5416 could
neither inhibit the activation of pro-apoptotic ERK pathway, nor
reverse the decrease of pro-survival Akt pathway, suggesting that
the neuroprotective effect of SU5416 is independent from the
regulation of the PI3-K/Akt and ERK pathways.
It is well-known that NO is a central pro-apoptotic factor
mediating the neurotoxicity of MPP+/MPTP both in vitro and in
vivo [25,28]. Intracellular NO could form peroxynitrite by reacting
with superoxide, a kind of reactive oxygen species overproduced in
MPP+-treated neurons. The resulted peroxynitrite could directly
cause neuronal loss by nitrating cellular protein, damaging DNA
and disrupting mitochondria [29]. We found that SU5416
decreased the elevated level of intracellular NO induced by
MPP+, which suggested that SU5416 might exert its neuropro-
tective effects by regulating NO formation. Endogenous NO is
mainly produced by a family of NOS enzymes. Three isoforms of
NOS, namely nNOS (NOS-1), iNOS (NOS-2) and endothelial
NOS (eNOS, NOS-3), have been identified so far. It is noteworthy
that ablation of eNOS has no bearing on MPP+-induced
neurotoxicity [28]. In the present study, we demonstrated that
MPP+ increased the expression of nNOS, but not iNOS in CGNs.
nNOS inhibitor 7-nitroindazole, but not iNOS inhibitor 1400 W,
reduced MPP+-induced neuronal loss. These results suggested that
MPP+-induced neurotoxicity was mainly mediated by the over-
activation of nNOS, and SU5416 prevented neurotoxicity possibly
by targeting nNOS.
According to Western blotting analysis, SU5416 reduced
MPP+-elevated protein expression of nNOS. By assaying in vitro
NOS activity, we further demonstrated that SU5416 directly
inhibited the activity of nNOS with IC50 value of 22.7 mM. Most
importantly, nNOS depletion abolished the neuroprotective effects
of SU5416 against MPP+-induced neuronal death. These results
strongly suggested that SU5416 most likely prevented NO-
mediated neurotoxicity via both inhibiting the activity and
decreasing the expression of nNOS. Although the precise
mechanisms underlying the decrease of nNOS expression induced
by SU5416 is still unclear, a recent study demonstrated that
SU5416 could down-regulate the PI3K/Akt signaling pathway, a
critical mediator in the activation of nNOS gene transcription
induced by retinoic acid [30], suggesting that SU5416 might
reduce the protein expression of nNOS via down-regulating the
Akt pathway.
The production of neurotoxic NO by nNOS is implicated in
many neurodegenerative disorders. Selective nNOS inhibitors
may thus have therapeutic potential in treating neurodegenerative
disorders by preventing neuronal death [31]. In this study, we
have shown for the first time that SU5416 possesses neuroprotec-
tive potential against MPP+/MPTP-induced neurotoxicity both in
vitro and in vivo. We have also demonstrated that SU5416 prevents
neurotoxicity by reducing nNOS protein expression and directly
inhibiting the enzyme activity of nNOS. In view of the capability
of SU5416 to cross the blood-brain barrier and the safety for
human use, our findings further indicate that SU5416 might be a
novel drug candidate for neurodegenerative disorders and CNS
cancers, particularly those associated with NO-mediated neuro-
toxicity.
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